Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
Crossref DOI link: https://doi.org/10.1007/s00280-015-2712-0
Published Online: 2015-02-27
Published Print: 2015-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Papadopoulos, Kyriakos P.
Isaacs, Randi
Bilic, Sanela
Kentsch, Kerstin
Huet, Heather A.
Hofmann, Matthias
Rasco, Drew
Kundamal, Nicole
Tang, Zhongwhen
Cooksey, Jennifer
Mahipal, Amit
Text and Data Mining valid from 2015-02-27